Geographic Variation of Chronic Opioid Use in Fibromyalgia

Clinical Therapeutics

Volumn 35, Issue 3, 2013, Pages 303-311

  Painter, Jacob T ^a,b   Crofford, Leslie J ^c   Talbert, Jeffery ^d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d University of Kentucky   (United States)

Author keywords

Chronic nonmalignant pain; Fibromyalgia; FM; Geographic variation; Opioid

Indexed keywords

OPIATE;

ADULT; ARTICLE; CHRONIC OPIOID USE; DEMOGRAPHY; DOCTOR PATIENT RELATION; DRUG MONITORING; DRUG TRAFFIC; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; FIBROMYALGIA; HEALTH INSURANCE; HUMAN; INFORMATION DISSEMINATION; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PHYSICIAN; PRESCRIPTION; PREVALENCE; SEX;

ANALGESICS, OPIOID; COHORT STUDIES; DRUG UTILIZATION REVIEW; FEMALE; FIBROMYALGIA; GEOGRAPHY; HUMANS; MALE;

EID: 84874994095     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.02.003     Document Type: Article

References (36)

1. Buskila D. Developments in the scientific and clinical understanding of fibromyalgia. Arthritis Res Ther 2009, 11:242.
2. Neumann L., Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep 2003, 7:362-368.
3. White K.P., Harth M., Speechley M., Ostbye T. Testing an instrument to screen for fibromyalgia syndrome in general population studies: the London Fibromyalgia Epidemiology Study Screening Questionnaire. J Rheumatol 1999, 26:880-884.
4. Berger A., Dukes E., Martin S., et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007, 61:1498-1508.
5. White K.P., Speechley M., Harth M., Ostbye T. The London Fibromyalgia Epidemiology Study: direct health care costs of fibromyalgia syndrome in London, Canada. J Rheumatol 1999, 26:885-889.
6. Goldenberg D.L., Burckhardt C., Crofford L. Management of fibromyalgia syndrome. JAMA 2004, 292:2388-2395.
7. Chou R., Fanciullo G.J., Fine P.G., et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009, 10:113-130.
8. Painter J.T., Crofford L. Chronic opioid use in fibromyalgia: a clinical review. J Clin Rheumatol 2013 Jan 29, [Epub ahead of print].
9. Williams D.A., Clauw D.J. Understanding fibromyalgia: lessons from the broader pain research community. J Pain 2009, 10:777-791.
10. Crofford L.J. Adverse effects of chronic opioid therapy for chronic musculoskeletal pain. Nature reviews. Rheumatology 2010, 6:191-197.
11. Landrum M.B., Meara E.R., Chandra A., et al. Is spending more always wasteful?. The appropriateness of care and outcomes among colorectal cancer patients. Health Aff (Millwood) 2008, 27:159-168.
12. Guadagnoli E., Landrum M.B., Normand S.L., et al. Impact of underuse, overuse, and discretionary use on geographic variation in the use of coronary angiography after acute myocardial infarction. Med Care 2001, 39:446-458.
13. Lopez J., Meier J., Cunningham F., Siegel D. Antihypertensive medication use in the Department of Veterans Affairs: a national analysis of prescribing patterns from 2000 to 2002. Am J Hypertens 2004, 17(12 pt 1):1095-1099.
14. Cox E.R., Motheral B.R., Henderson R.R., Mager D. Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample. Pediatrics 2003, 111:237-243.
15. Curtis L.H., Stoddard J., Radeva J.I., et al. Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Serv Res 2006, 41(3 pt 1):837-855.
16. Webster B.S., Cifuentes M., Verma S., Pransky G. Geographic variation in opioid prescribing for acute, work-related, low back pain and associated factors: a multilevel analysis. Am J Ind Med 2009, 52:162-171.
17. Wennberg J.E., Freeman J.L., Culp W.J. Are hospital services rationed in New Haven or over-utilised in Boston?. Lancet 1987, 1:1185-1189.
18. Carville S.F., Arendt-Nielsen S., Bliddal H., et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008, 67:536-541.
19. McDonald D.C., Carlson K., Izrael D. Geographic variation in opioid prescribing in the U.S. J Pain 2012, 13:988-996.
20. Zerzan J.T., Morden N.E., Soumerai S., et al. Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002. Med Care 2006, 44:1005-1010.
21. Simoni-Wastila L., Ritter G., Strickler G. Gender and other factors associated with the nonmedical use of abusable prescription drugs. Subst Use Misuse 2004, 39:1-23.
22. Reid M.C., Engles-Horton L.L., Weber M.B., et al. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med 2002, 17:173-179.
23. AHFS pharmacologic-therapeutic classification system, 2011 ASHP Drug Information, Accessed August 17, 2011. http://www.ahfsdruginformation.com/class/index.aspx.
24. Pharmaprojects Therapeutic Class Codes, 2009 DIALOG, Accessed August 18, 2011. http://support.dialog.com/searchaids/dialog/pdf/f128_therapeuticcodes.pdf.
25. Russell I.J., Kamin M., Bennett R.M., et al. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000, 6:250-257.
26. Substance Abuse and Mental Health Services Administration. Summary of Findings From the 2007 National Household Survey on Drug Abuse: Volume II. Technical Appendices and Selected Data Tables. Rockville, MD. 2004///2008.
27. Special data request on State Licensing Information from Redi-Data, Inc. 2012 This is Kaiser Family Foundation, Accessed January 25, 2013. http://www.statehealthfacts.org/comparecat.jsp?cat=8&rgn=6&rgn=1.
28. Weissman R. Ranking of state medical board serious disciplinary actions, 2008 Accessed August 24, 2011. http://www.citizen.org/publications/release.
29. Tallon J.R. State scorecards, 2010 Accessed August 24, 2011. http://www.commonwealthfund.org/Maps-and-Data/State-Data-Center/State-Scorecard.aspx.
30. Fischer E. Quality and effective care, 2008 Accessed August 24, 2011. http://www.dartmouthatlas.org/data/topic/topic.aspx?cat=25.
31. Wolfe F., Anderson J., Harkness D., et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997, 40:1560-1570.
32. Green T.C., Mann M.R., Bowman S.E., et al. How does use of a prescription monitoring program change medical practice?. Pain Med 2012, 13:1314-1323.
33. Paulozzi L.J., Kilbourne E.M., Desai H.A. Prescription drug monitoring programs and death rates from drug overdose. Pain Med 2011, 12:747-754.
34. Reisman R., Shenoy P., Atherly A., Flowers C. Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy. Substance Abuse Res Treat 2009, 3:41-51.
35. Healthleaders, Inc, special data request, June 2012 Kaiser Family Foundation, Accessed January 25, 2013. http://www.statehealthfacts.org/comparecat.jsp?cat=7&rgn=6&rgn=1.
36. Westert G.P., Groenewegen P.P. Medical practice variations: changing the theoretical approach. Scand J Public Health 1999, 27:173-180.